Get 50% OFF This Summer!

Advertisement
logo

Nectar Lifescience

NECLIFE
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Nectar Lifescience Share price and Fundamental Analysis

View All Details
View All Details
Nectar Lifesciences Ltd (NLL or NECLIFE) is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. The company manufactures Cephalosporin Active pharmaceutical ingredients, finished dosage forms, Phytochemicals, and hard gelatin capsules at their facilities spread across three Indian states of Punjab, Himachal Pradesh and Jammu. They have developed sustainable production systems to manufacture high quality intermediates and APIs to meet the diverse requirements of their customer base in India and over 90 countries worldwide.
Company Incorporation1995
ChairmanSanjiv Goyal
Head QuartersChandigarh
Previous NameNA

Key Metrics

Market Cap (Cr)
460.41
PE Ratio
27.01
Industry P/E
35.07
PEG Ratio
0.24
ROE
1%
ROCE
6.79%
ROA
0.78%
Total Debt (Cr)
629.12
Debt to Equity
0.58
Dividend Yield
0%
EPS
0.76
Book Value & P/B
48.06 x 0.43
Face Value
1
Outstanding Shares(Cr)
22.43
Current Ratio
2.79
EV to Sales
0.56

Stock Returns

1 Week-3.48%
1 Month-7.1%
6 Months-41.5%
1 Year-36.95%
3 Years-14.22%
5 Years+52.06%

CAGR

1 Year CAGR

Revenue Growth

+10.26%

Net Profit Growth

-120.66%

Operating Profit Growth

+72.72%

Dividend Growth

N/A

Stock Returns CAGR

-38.04%
no_data

No Stocks

Smart Score

2.3
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 44.53%

FIIs : 1.65%

DIIs : 0.16%

Public : 53.67%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 99.6% of holding in March 2025 Qtr
FII Shareholding Increased by 0.91% to 1.65% in March 2025 Qtr
DII Shareholding Increased by 0.16% to 0.16% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Nectar Lifescience Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Nectar Lifescience Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Nectar Lifesciences Ltd (NLL or NECLIFE) is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. The company manufactures Cephalosporin Active pharmaceutical ingredients, finished dosage forms, Phytochemicals, and hard gelatin capsules at their facilities spread across three Indian states of Punjab, Himachal Pradesh and Jammu. They have developed sustainable production systems to manufacture high quality intermediates and APIs to meet the diverse requirements of their customer base in India and over 90 countries worldwide.

The company's business operations are primarily concentrated on manufacturing and marketing of oral and sterile cephalosporins, phytochemicals and allied products. They manufacture and sell a range of cephalosporins and phytochemicals. They are also engaged in contract manufacturing of API's for pharmaceutical players.

Nectar Lifesciences Ltd was incorporated on June 27, 1995 as a public limited company with the name Surya Medicare Ltd. The company was established pursuant to a financial collaboration agreement between the Promoters and Punjab State Industrial Development Corporation.

In April 1997, the company commenced business with the commercial production of Oral Bulk Drugs at their manufacturing facility located in the B Category zone of Punjab. In March 1998, they started the production of Sterile Bulk Drugs. In the year 1999, they added the formulation facilities by setting up a vial filing section for Crystalline Sterile Bulk Drugs.

In the year 2000, the company undertook an expansion by increasing the installed capacity Crystalline Sterile Bulk Drugs from 406 MT to 810 MT. In the year 2001, they also installed one Crystalline section of 65 MT per annum, which commenced production in October 2001.

In the year 2002, the company undertook another expansion programme increasing the production capacity for Cephalosporin Sterile. In October 18, 2002, they incorporated Chempharma (Pvt) Ltd as a wholly-owned subsidiary company in Sri Lanka to manufacture API intermediaries.

In the year 2003, the company commenced modernization / expansion plan for increasing our presence in the Cephalosporins segment. In April 2003, the company bought back the entire shareholding of PSIDC at a price of Rs 16.47 per share under the One Time Settlement policy announced by Government of Punjab - Industrial Policy, 2003.

In the year 2004, the company started production in a portion of the new Cephalosporins plant. In March 26, 2004, the company changed their name from Surya Medicare Ltd to Nectar Lifesciences Ltd.

During the year 2006-07, the company commissioned a state-of-the-art facility dedicated to the non-antibiotic therapeutic segment in compliance with stringent US-FDA and EDQM guidelines. The company established a state-of-the-art mint derivatives plant, initiating its business activity into the phytochemicals arena. They also up a menthol flakes facilities at SIDCO Industrial Complex, Jammu to add to the requisite business activity with all the locational benefits to the industry in J&K. They commissioned a unit in Derabassi to process menthol into powder and crystal forms

The company also established an Empty Hard Gelatin Capsule unit at Baddi, Himachal Pradesh referred to as Unit VII which commenced production with effect from April 2007. In April 2008, they set up a state-of-the-art facility, Unit X at Derabassi, which commissioned on April 17, 2008.

During the year 2008-09, the company increased the production capacity of Bulk Drug & Sterile from 425 MT to 650 MT. Also, they increased the production capacity of Phytochemicals - Menthol from 6000 MT to 7600 MT. They launched 30 formulation brands (P2P). Also, they established a fully-owned formulation R&D centre in Derabassi dedicated to non-cephalosporins related developments like oncology, anti-diabetes, cardiovascular system, female healthcare and anti-HIV.

During the year 2009-10, the company increased the production capacity of Bulk Drug & Sterile from 650 MT to 1600 MT. Also, they launched the diagnostic division during the year.

During FY 2010-11, M/s Nectar Capital Limited was incorporated in Mauritius and M/s Nectar Lifesciences UK Limited, was incorporated in United Kingdom. Nectar Lifesciences US, LLC in United States was also incorporated during year 2014-15, which commenced the business operations of trading in pharmeceutical products.

In March 2011, the company received approval from the Japanese MOH for their product, Cefuroxime Axetil.

The company incorporated a WOS namely NECLIFE PT, UNIPESSOAL LDA in Portugal on July 11, 2019 to takeover MA from Nectar Lifesciences UK Limited. Two new innovative products in EHGC - menthol capsules (Nexxicap MintyTM) and pearl capsule (Nexxicap PearlTM) were launched in 2019-20.

Nectar Lifescience Share Price

Nectar Lifescience share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Nectar Lifescience Market Cap

Market capitalization of Nectar Lifescience indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Nectar Lifescience is valued compared to its competitors.

Nectar Lifescience PE Ratio

Nectar Lifescience PE ratio helps investors understand what is the market value of each stock compared to Nectar Lifescience 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Nectar Lifescience PEG Ratio

The PEG ratio of Nectar Lifescience evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Nectar Lifescience ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Nectar Lifescience generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Nectar Lifescience ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Nectar Lifescience in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Nectar Lifescience Total Debt

Total debt of Nectar Lifescience shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Nectar Lifescience Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Nectar Lifescience compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Nectar Lifescience CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Nectar Lifescience over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Nectar Lifescience Technical Analysis

Technical analysis of Nectar Lifescience helps investors get an insight into when they can enter or exit the stock. Key components of Nectar Lifescience Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Nectar Lifescience shares often struggle to rise above due to selling pressure.

Nectar Lifescience Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Nectar Lifescience ’s financial health and profitability.

Nectar Lifescience Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Nectar Lifescience Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Nectar Lifescience Financials

The financials of Nectar Lifescience provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Nectar Lifescience Profit and Loss Statements

The profit and loss statement of Nectar Lifescience highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Nectar Lifescience .

Nectar Lifescience Balance Sheet

The balance sheet presents a snapshot of Nectar Lifescience ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Nectar Lifescience Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App